Cardiol Therapeutics (CRDL) Cash from Financing Activities (2020 - 2026)
Cardiol Therapeutics (CRDL) posted Cash from Financing Activities of $9.9 million for Q1 2026, down 11.05% on a QoQ basis from $11.1 million in Q4 2025, and up 102887.35% year-over-year from N/an in Q1 2025.
Cardiol Therapeutics (CRDL) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Cardiol Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $9.9 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 102887.35% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.1 million (up 56.96% YoY) and the FY2025 annual result came in at $11.1 million, down 17.38% from the prior year.
- Cash from Financing Activities was $9.9 million for Q1 2026 at Cardiol Therapeutics, down from $11.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $13.4 million in Q4 2024 and bottomed at -$10614.8 in Q3 2022.
- A 5-year average of $2.0 million and a median of -$10059.5 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 131673.49% — and 2025, when it slumped 197.35%.
- Cardiol Therapeutics' Cash from Financing Activities stood at -$10198.9 in 2022, then increased by 0.29% to -$10168.9 in 2023, then jumped by 131673.49% to $13.4 million in 2024, then slipped by 16.67% to $11.1 million in 2025, then retreated by 11.05% to $9.9 million in 2026.
- Business Quant data shows CRDL's Cash from Financing Activities at $9.9 million in Q1 2026, $11.1 million in Q4 2025, and -$10059.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Cardiol Therapeutics | 134.05 Mn | 134.05 Mn | - | 9.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.92 Mn |
| Mar 31, 2026 | 9.92 Mn |
| Dec 31, 2025 | 11.15 Mn |
| Dec 31, 2025 | 11.15 Mn |
| Sep 30, 2025 | -10,059.53 |
| Sep 30, 2025 | -10,059.53 |
| Jun 30, 2025 | 14,734.48 |
| Jun 30, 2025 | 14,734.48 |
| Mar 31, 2025 | -9,648.11 |
| Mar 31, 2025 | -9,648.11 |
| Dec 31, 2024 | 13.38 Mn |
| Dec 31, 2024 | 13.38 Mn |
| Sep 30, 2024 | -3,383.04 |
| Sep 30, 2024 | -3,383.04 |
| Jun 30, 2024 | 57,090.38 |
| Jun 30, 2024 | 57,090.38 |
| Mar 31, 2024 | 56,662.57 |
| Mar 31, 2024 | 56,662.57 |
| Dec 31, 2023 | -10,168.91 |
| Dec 31, 2023 | -10,168.91 |